143 related articles for article (PubMed ID: 9276358)
1. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.
Sartor CI; Strawderman MH; Lin XH; Kish KE; McLaughlin PW; Sandler HM
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):941-7. PubMed ID: 9276358
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
3. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
Aref I; Eapen L; Agboola O; Cross P
Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
[TBL] [Abstract][Full Text] [Related]
4. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
5. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
6. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.
Thames H; Kuban D; Levy L; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):929-43. PubMed ID: 14575823
[TBL] [Abstract][Full Text] [Related]
7. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
Zagars GK; Pollack A; Smith LG
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
[TBL] [Abstract][Full Text] [Related]
8. Cryosurgical ablation of prostate cancer: patterns of cancer recurrence.
Shinohara K; Rhee B; Presti JC; Carroll PR
J Urol; 1997 Dec; 158(6):2206-9; discussion 2209-10. PubMed ID: 9366345
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Lee WR; Hanlon AL; Hanks GE
J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
[TBL] [Abstract][Full Text] [Related]
10. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Crook JM; Bahadur YA; Bociek RG; Perry GA; Robertson SJ; Esche BA
Cancer; 1997 Jan; 79(2):328-36. PubMed ID: 9010106
[TBL] [Abstract][Full Text] [Related]
12. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
Kuban DA; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):915-28. PubMed ID: 14575822
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Pollack A; Zagars GK; Kavadi VS
Cancer; 1994 Jul; 74(2):670-8. PubMed ID: 7518341
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
16. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.
Mydin AR; Dunne MT; Finn MA; Armstrong JG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):101-8. PubMed ID: 22658512
[TBL] [Abstract][Full Text] [Related]
17. Practical application of biochemical failure definitions: what to do and when to do it.
Kestin LL; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):304-15. PubMed ID: 12023134
[TBL] [Abstract][Full Text] [Related]
18. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
Pollack A; Zagars GK; el-Naggar AK; Terry NH
Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
[TBL] [Abstract][Full Text] [Related]
19. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
Lee WR; Hanks GE; Hanlon A
J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
